IPS Cell-based Therapy for Parkinson's Disease: A Kyoto Trial

Overview

Journal Regen Ther

Date 2021 Jan 25

PMID 33490319

Citations 72

Authors

Jun Takahashi

Affiliations

Soon will be listed here.

Abstract

Following intensive efforts since their discovery little more than 10 years ago, cell replacement therapy using induced pluripotent stem (iPS) cells is now becoming reality. However, there remain several obstacles in the translation of basic research to clinical application, obstacles known as the "Valley of Death". With regards to regenerative medicine using iPS cells for Parkinson's disease, we have developed a method for the 1) efficient induction of dopaminergic neurons from human iPS cells and 2) sorting dopaminergic progenitor cells using a floor plate marker, CORIN. The grafted CORIN cells survived well and functioned as midbrain dopaminergic neurons in the Parkinson's disease model rats and monkeys, and showed minimal risk of tumor formation. Based on these results, we performed a pre-clinical study using a clinical-grade iPS cell line and finally started a clinical trial to treat Parkinson's disease patients in August 2018. Here, I discuss the key issues to crossing the Valley of Death: scientific rationale, pre-clinical study, and clinical trial.

Citing Articles

Relationship Between Location of Cell Transplantation and Recovery for Intracerebral Stem Cell Transplantation for Chronic Traumatic Brain Injury: Analysis of STEMTRA Trial.

Kawabori M, Karasawa Y, Suenaga J, Nakamura H, Imai H, Yasuhara T Neurotrauma Rep. 2025; 6(1):106-114.

PMID: 39990703 PMC: 11839542. DOI: 10.1089/neur.2024.0130.

Mapping the global clinical landscape of stem cell therapies for neurological diseases from 1998 to 2023: an analysis based on the Trialtrove database.

Jiang S, Bao X, Zhong C, Wang R Stem Cell Res Ther. 2025; 16(1):41.

PMID: 39901212 PMC: 11792730. DOI: 10.1186/s13287-024-04096-2.

Research of reprogramming toward clinical applications in regenerative medicine: A concise review.

Nakatsukasa Y, Yamada Y, Yamada Y Regen Ther. 2024; 28:12-19.

PMID: 39678397 PMC: 11638634. DOI: 10.1016/j.reth.2024.11.008.

The Abnormal Proliferation of Midbrain Dopamine Cells From Human Pluripotent Stem Cells Is Induced by Exposure to the Tumor Microenvironment.

Xue J, Wu D, Bao Y, Wu Y, Zhang X, Chen L CNS Neurosci Ther. 2024; 30(11):e70117.

PMID: 39563017 PMC: 11576488. DOI: 10.1111/cns.70117.

Human iPSC-derived neural stem cells displaying radial glia signature exhibit long-term safety in mice.

Luciani M, Garsia C, Beretta S, Cifola I, Peano C, Merelli I Nat Commun. 2024; 15(1):9433.

PMID: 39487141 PMC: 11530573. DOI: 10.1038/s41467-024-53613-7.

References

Chambers S, Fasano C, Papapetrou E, Tomishima M, Sadelain M, Studer L . Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009; 27(3):275-80. PMC: 2756723. DOI: 10.1038/nbt.1529. View

Doi D, Morizane A, Kikuchi T, Onoe H, Hayashi T, Kawasaki T . Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease. Stem Cells. 2012; 30(5):935-45. DOI: 10.1002/stem.1060. View

Doi D, Magotani H, Kikuchi T, Ikeda M, Hiramatsu S, Yoshida K . Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease. Nat Commun. 2020; 11(1):3369. PMC: 7338530. DOI: 10.1038/s41467-020-17165-w. View

Katsukawa M, Nakajima Y, Fukumoto A, Doi D, Takahashi J . Fail-Safe Therapy by Gamma-Ray Irradiation Against Tumor Formation by Human-Induced Pluripotent Stem Cell-Derived Neural Progenitors. Stem Cells Dev. 2016; 25(11):815-25. DOI: 10.1089/scd.2015.0394. View

Xi J, Liu Y, Liu H, Chen H, Emborg M, Zhang S . Specification of midbrain dopamine neurons from primate pluripotent stem cells. Stem Cells. 2012; 30(8):1655-63. PMC: 3405174. DOI: 10.1002/stem.1152. View

Kriks S, Shim J, Piao J, Ganat Y, Wakeman D, Xie Z . Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011; 480(7378):547-51. PMC: 3245796. DOI: 10.1038/nature10648. View

Doi D, Samata B, Katsukawa M, Kikuchi T, Morizane A, Ono Y . Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports. 2014; 2(3):337-50. PMC: 3964289. DOI: 10.1016/j.stemcr.2014.01.013. View

Politis M, Wu K, Loane C, Quinn N, Brooks D, Rehncrona S . Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med. 2010; 2(38):38ra46. DOI: 10.1126/scitranslmed.3000976. View

Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S . A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011; 8(5):409-12. DOI: 10.1038/nmeth.1591. View

10.

Murry C, Keller G . Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell. 2008; 132(4):661-80. DOI: 10.1016/j.cell.2008.02.008. View

11.

Barker R, Barrett J, Mason S, Bjorklund A . Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol. 2012; 12(1):84-91. DOI: 10.1016/S1474-4422(12)70295-8. View

12.

Ono Y, Nakatani T, Sakamoto Y, Mizuhara E, Minaki Y, Kumai M . Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development. 2007; 134(17):3213-25. DOI: 10.1242/dev.02879. View

13.

Bye C, Jonsson M, Bjorklund A, Parish C, Thompson L . Transcriptome analysis reveals transmembrane targets on transplantable midbrain dopamine progenitors. Proc Natl Acad Sci U S A. 2015; 112(15):E1946-55. PMC: 4403171. DOI: 10.1073/pnas.1501989112. View

14.

Steinbeck J, Choi S, Mrejeru A, Ganat Y, Deisseroth K, Sulzer D . Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model. Nat Biotechnol. 2015; 33(2):204-9. PMC: 5117952. DOI: 10.1038/nbt.3124. View

15.

Kirkeby A, Grealish S, Wolf D, Nelander J, Wood J, Lundblad M . Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep. 2012; 1(6):703-14. DOI: 10.1016/j.celrep.2012.04.009. View

16.

Li W, Englund E, Widner H, Mattsson B, van Westen D, Latt J . Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A. 2016; 113(23):6544-9. PMC: 4988567. DOI: 10.1073/pnas.1605245113. View

17.

Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D . Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci. 2007; 27(30):8011-22. PMC: 6672736. DOI: 10.1523/JNEUROSCI.2079-07.2007. View

18.

Olanow C, Brundin P . Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?. Mov Disord. 2013; 28(1):31-40. DOI: 10.1002/mds.25373. View

19.

Barker R, Drouin-Ouellet J, Parmar M . Cell-based therapies for Parkinson disease—past insights and future potential. Nat Rev Neurol. 2015; 11(9):492-503. DOI: 10.1038/nrneurol.2015.123. View

20.

Barker R, Parmar M, Studer L, Takahashi J . Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era. Cell Stem Cell. 2017; 21(5):569-573. DOI: 10.1016/j.stem.2017.09.014. View